Phio Pharmaceuticals Corp.
PHIO
$2.36
-$0.04-1.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -42.38% | -67.63% | -70.74% | -55.53% | -62.26% |
| Gross Profit | 42.38% | 67.63% | 70.74% | 55.53% | 62.26% |
| SG&A Expenses | -7.33% | -14.25% | -18.98% | -20.12% | -18.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.23% | -30.95% | -35.77% | -30.35% | -25.10% |
| Operating Income | 24.23% | 30.95% | 35.77% | 30.35% | 25.10% |
| Income Before Tax | 27.86% | 33.96% | 36.38% | 30.37% | 24.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.86% | 33.96% | 36.38% | 30.37% | 24.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.86% | 33.96% | 36.38% | 30.37% | 24.61% |
| EBIT | 24.23% | 30.95% | 35.77% | 30.35% | 25.10% |
| EBITDA | 23.92% | 30.61% | 35.54% | 30.22% | 25.04% |
| EPS Basic | 76.41% | 87.74% | 84.63% | 78.13% | 69.80% |
| Normalized Basic EPS | 76.11% | 87.66% | 85.14% | 78.54% | 70.19% |
| EPS Diluted | 76.40% | 87.74% | 84.63% | 78.14% | 69.81% |
| Normalized Diluted EPS | 76.11% | 87.66% | 85.14% | 78.54% | 70.19% |
| Average Basic Shares Outstanding | 29.14% | 680.69% | 795.03% | 895.60% | 961.74% |
| Average Diluted Shares Outstanding | 29.14% | 680.69% | 795.03% | 895.60% | 961.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |